Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cullinan Therapeutics Inc (CGEM)

Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 612,618
  • Shares Outstanding, K 59,076
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,380 K
  • EBIT $ -241 M
  • EBITDA $ -241 M
  • 60-Month Beta -0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34

Options Overview Details

View History
  • Implied Volatility 186.68% (-92.22%)
  • Historical Volatility 121.27%
  • IV Percentile 67%
  • IV Rank 18.67%
  • IV High 740.76% on 09/19/25
  • IV Low 59.52% on 08/18/25
  • Expected Move (DTE 20) 1.52 (14.67%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 62
  • Volume Avg (30-Day) 853
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 6,374
  • Open Int (30-Day) 18,299
  • Expected Range 8.85 to 11.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.80
  • Number of Estimates 7
  • High Estimate -0.54
  • Low Estimate -0.99
  • Prior Year -0.73
  • Growth Rate Est. (year over year) -9.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.48 +9.39%
on 12/17/25
13.10 -20.84%
on 12/11/25
-1.37 (-11.67%)
since 11/26/25
3-Month
5.68 +82.57%
on 10/03/25
13.33 -22.21%
on 11/24/25
+4.41 (+73.99%)
since 09/26/25
52-Week
5.68 +82.57%
on 10/03/25
13.33 -22.21%
on 11/24/25
-2.53 (-19.61%)
since 12/26/24

Most Recent Stories

More News
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML ...

CGEM : 10.37 (+1.07%)
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01,...

CGEM : 10.37 (+1.07%)
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass. , Nov. 20, 2025 /PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced...

CGEM : 10.37 (+1.07%)
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune...

CGEM : 10.37 (+1.07%)
Cullinan Therapeutics: Q3 Earnings Snapshot

Cullinan Therapeutics: Q3 Earnings Snapshot

CGEM : 10.37 (+1.07%)
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be...

CGEM : 10.37 (+1.07%)
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate...

CGEM : 10.37 (+1.07%)
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM),...

CGEM : 10.37 (+1.07%)
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Nuvation Bio (NUVB) and QT Imaging Holdings (OtherQTIH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cullinan Management (CGEM – Research Report), Nuvation Bio (NUVB – Research Report) and QT Imaging Holdings...

CGEM : 10.37 (+1.07%)
QTIH : 5.9500 (+5.12%)
NUVB : 9.40 (-1.26%)
Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

PRINCETON, N.J. and CAMBRIDGE, Mass. , Oct. 12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the central nervous system (CNS) involvement...

CGEM : 10.37 (+1.07%)

Business Summary

Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 10.92
2nd Resistance Point 10.67
1st Resistance Point 10.52
Last Price 10.37
1st Support Level 10.12
2nd Support Level 9.87
3rd Support Level 9.72

See More

52-Week High 13.33
Fibonacci 61.8% 10.41
Last Price 10.37
Fibonacci 50% 9.51
Fibonacci 38.2% 8.60
52-Week Low 5.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar